Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma
| Autor: | Morio Yamazaki, M. Kano, T. Kitabatake, T. Monma, Hiroshi Hasegawa, Eiju Sato, Tetsuharu Kaneko, Etsuro Takeishi, Manabu Endo, Chihiro Kanno |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Docetaxel Gastroenterology 03 medical and health sciences Peplomycin 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Biopsy medicine Humans Stage (cooking) Adverse effect Cisplatin Chemotherapy medicine.diagnostic_test business.industry 030206 dentistry Otorhinolaryngology Fluorouracil 030220 oncology & carcinogenesis Carcinoma Squamous Cell Mouth Neoplasms Taxoids Surgery Neoplasm Recurrence Local Oral Surgery business medicine.drug |
| Zdroj: | International Journal of Oral and Maxillofacial Surgery. 49:984-992 |
| ISSN: | 0901-5027 |
| Popis: | The objectives of this study were to evaluate survival in 141 patients with stage II-IV oral squamous cell carcinoma (OSCC) treated with preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil (IADCPIVF) via the superficial temporal artery, and to clarify the prognostic factors. The study population included 59 patients with stage II OSCC, 34 with stage III, and 48 with stage IV. After IADCPIVF, 139 patients underwent surgery; minimally invasive surgeries (MIS) including excisional biopsy were performed on 96 patients with a remarkably good response to IADCPIVF. The primary tumour response rate was 99.3% (complete response rate 56.7%, good partial response rate 17.0%, fair partial response rate 25.5%). Additionally, there were no serious adverse events associated with IADCPIVF. The 5-year overall survival rate was 74.6% (stage II 83.6%, stage III 72.7%, stage IV 64.8%). In the multivariate analysis of survival, T classification and clinical tumour response were significant prognostic factors. Eight (8.3%) of the patients who received MIS had primary recurrence and six were salvaged. In conclusion, IADCPIVF is safe and efficacious for treating OSCC, and MIS could reduce the extent of primary tumour resection in the case of a remarkably good response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect